These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28544586)

  • 61. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model.
    Shimazaki N; Togashi N; Hanai M; Isoyama T; Wada K; Fujita T; Fujiwara K; Kurakata S
    Eur J Cancer; 2008 Aug; 44(12):1734-43. PubMed ID: 18511262
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Peroxisome proliferator-activated receptors increase human sebum production.
    Trivedi NR; Cong Z; Nelson AM; Albert AJ; Rosamilia LL; Sivarajah S; Gilliland KL; Liu W; Mauger DT; Gabbay RA; Thiboutot DM
    J Invest Dermatol; 2006 Sep; 126(9):2002-9. PubMed ID: 16675962
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hyperbaric oxygen preconditioning protects cortical neurons against oxygen-glucose deprivation injury: role of peroxisome proliferator-activated receptor-gamma.
    Zeng Y; Xie K; Dong H; Zhang H; Wang F; Li Y; Xiong L
    Brain Res; 2012 May; 1452():140-50. PubMed ID: 22444276
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta.
    Knight B; Yeap BB; Yeoh GC; Olynyk JK
    Carcinogenesis; 2005 Oct; 26(10):1782-92. PubMed ID: 15917308
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition of the Lipid Droplet-Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties.
    Kuramoto K; Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Kitanaka C; Okada M
    Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33466690
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PPARgamma signaling: one size fits all?
    Jain A; Agus DB
    Cell Cycle; 2004 Nov; 3(11):1352-4. PubMed ID: 15467471
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARalpha activation.
    Cano C; Pavón J; Serrano A; Goya P; Paez JA; de Fonseca FR; Macias-Gonzalez M
    J Med Chem; 2007 Jan; 50(2):389-93. PubMed ID: 17228882
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Aromatic sulfonamides containing a condensed piperidine moiety as potential oxidative stress-inducing anticancer agents.
    Madácsi R; Kanizsai I; Fehér LZ; Gyuris M; Ozsvári B; Erdélyi A; Wölfling J; Puskás LG
    Med Chem; 2013 Nov; 9(7):911-9. PubMed ID: 23270324
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A promising in silico protocol to develop novel PPARγ antagonists as potential anticancer agents: Design, synthesis and experimental validation via PPARγ protein activity and competitive binding assay.
    Sivamani Y; Shanmugarajan D; Durai Ananda Kumar T; Faizan S; Channappa B; Naishima NL; Prashantha Kumar BR
    Comput Biol Chem; 2021 Dec; 95():107600. PubMed ID: 34794076
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design and development of oxazol-5-ones as potential partial PPAR-γ agonist against cancer cell lines.
    Pal T; Joshi H; Ramaa CS
    Anticancer Agents Med Chem; 2014; 14(6):872-83. PubMed ID: 24875128
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Identification of an irreversible PPARγ antagonist with potent anticancer activity.
    Peng Y; Zhang Q; Zielinski RM; Howells RD; Welsh WJ
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00693. PubMed ID: 33280279
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy?
    Dicitore A; Caraglia M; Colao A; Zappavigna S; Mari D; Hofland LJ; Persani L; Vitale G
    Curr Cancer Drug Targets; 2013 May; 13(4):460-71. PubMed ID: 23617255
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular recognition of agonist and antagonist for peroxisome proliferator-activated receptor-α studied by molecular dynamics simulations.
    Liu M; Wang L; Zhao X; Sun X
    Int J Mol Sci; 2014 May; 15(5):8743-52. PubMed ID: 24837836
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development of a novel class of peroxisome proliferator-activated receptor (PPAR) gamma ligands as an anticancer agent with a unique binding mode based on a non-thiazolidinedione scaffold.
    Yamamoto K; Tamura T; Nakamura R; Hosoe S; Matsubara M; Nagata K; Kodaira H; Uemori T; Takahashi Y; Suzuki M; Saito JI; Ueno K; Shuto S
    Bioorg Med Chem; 2019 Nov; 27(22):115122. PubMed ID: 31623970
    [TBL] [Abstract][Full Text] [Related]  

  • 75. f25, a novel synthetic quinoline derivative, inhibits tongue cancer cell invasion and survival by the PPAR pathway in vitro and vivo.
    Liu T; Yang L; Li Z; Sun M; Lv N
    Chem Biol Interact; 2024 Mar; 391():110891. PubMed ID: 38278315
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
    Ammazzalorso A; Bruno I; Florio R; De Lellis L; Laghezza A; Cerchia C; De Filippis B; Fantacuzzi M; Giampietro L; Maccallini C; Tortorella P; Veschi S; Loiodice F; Lavecchia A; Cama A; Amoroso R
    ACS Med Chem Lett; 2020 May; 11(5):624-632. PubMed ID: 32435362
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of zibotentan in colorectal cancer--letter.
    Vlachostergios PJ
    Mol Cancer Ther; 2014 Jun; 13(6):1673. PubMed ID: 24837079
    [No Abstract]   [Full Text] [Related]  

  • 78. Efficacy of zibotentan in colorectal cancer--response.
    Haque SU; Welch H; Dashwood M; Ramesh B; Loizidou M
    Mol Cancer Ther; 2014 Jun; 13(6):1674. PubMed ID: 24837078
    [No Abstract]   [Full Text] [Related]  

  • 79. Potent and Selective Benzothiazole-Based Antimitotics with Improved Water Solubility: Design, Synthesis, and Evaluation as Novel Anticancer Agents.
    Gallego-Yerga L; Ceña V; Peláez R
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376146
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-Inflammatory, Antioxidant, and WAT/BAT-Conversion Stimulation Induced by Novel PPAR Ligands: Results from Ex Vivo and In Vitro Studies.
    Recinella L; De Filippis B; Libero ML; Ammazzalorso A; Chiavaroli A; Orlando G; Ferrante C; Giampietro L; Veschi S; Cama A; Mannino F; Gasparo I; Bitto A; Amoroso R; Brunetti L; Leone S
    Pharmaceuticals (Basel); 2023 Feb; 16(3):. PubMed ID: 36986448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.